Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 20/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5633253 | 0.88 | CYP1A2 (0.42) | IDO1 | |
| Trifluoroacetic Acid SCHEMBL5631069 | 0.85 | IDO1 (0.41) | IDO1 | |
| Trifluoroacetic Acid SCHEMBL4982964 | 0.85 | IDO1 (0.41) | IDO1 | |
| SCHEMBL14443049 | 0.83 | IDO1 (0.45) | IDO1 | |
| SCHEMBL2516207 | 0.83 | IDO1 (0.45) | IDO1 | |
| SCHEMBL5630936 | 0.82 | MAPT (0.49) | — | |
| SCHEMBL14462463 | 0.81 | IDO1 (0.43) | IDO1 | |
| SCHEMBL5630468 | 0.80 | CYP1A2 (0.41) | — | |
| SCHEMBL5631062 | 0.79 | IDO1 (0.54) | IDO1 | |
| SCHEMBL2515983 | 0.79 | IDO1 (0.50) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971583-B1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORP (US) | 2015-03-25 | — | — | EP | claimed |
| US-8951536-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2015-02-10 | — | — | US | claimed |
| US-20130177590-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2013-07-11 | — | — | US | claimed |
| EP-1971583-A2 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Incyte Corporation (US) | 2008-09-24 | — | — | EP | claimed |
| US-20070185165-A1 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION | 2007-08-09 | — | — | US | claimed |
| WO-2007075598-A2 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2007-07-05 | — | — | WO | claimed |
| EP-1971583-B1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORP (US) | 2015-03-25 | — | — | EP | disclosed |
| US-8951536-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2015-02-10 | — | — | US | disclosed |
| US-20130177590-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2013-07-11 | — | — | US | disclosed |
| US-8450351-B2 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2013-05-28 | — | — | US | disclosed |
| US-20070185165-A1 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | INCYTE CORPORATION | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130177590-A1 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, HNMT | IDO1 1/4885 |
| US-20070185165-A1 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | IDO1, IDO2, HNMT | IDO1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.